MTOR and tuberous sclerosis: It is worth noting that Grabole et al.′s study demonstrated that mTOR inhibitors corrected translational dysfunction probably implicated in brain tumor hypertrophy but neither inflammation nor angiogenesis associated with transcriptional defects, suggesting the possibility of combining additional treatments for TSC patients based on their specific clinical manifestation [78].